Short Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Drops By 8.6%

AnaptysBio, Inc. (NASDAQ:ANAB) was the target of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 6,030,000 shares, a drop of 8.6% from the January 15th total of 6,600,000 shares. Currently, 23.3% of the company’s stock are sold short. Based on an average daily trading volume, of 662,000 shares, the days-to-cover ratio is currently 9.1 days.

AnaptysBio Stock Performance

ANAB opened at $21.22 on Tuesday. AnaptysBio has a one year low of $12.21 and a one year high of $41.31. The stock’s fifty day moving average is $15.75 and its 200-day moving average is $25.63. The company has a market capitalization of $645.72 million and a PE ratio of -3.49.

Insider Activity at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 65,184 shares of the stock in a transaction on Monday, December 30th. The stock was purchased at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the purchase, the director now directly owns 7,860,180 shares in the company, valued at $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently modified their holdings of ANAB. Tower Research Capital LLC TRC raised its stake in shares of AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of AnaptysBio in the 4th quarter worth $40,000. Values First Advisors Inc. acquired a new position in shares of AnaptysBio in the 3rd quarter worth $49,000. nVerses Capital LLC grew its holdings in shares of AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares during the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 4,237 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ANAB shares. Wedbush restated an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a research note on Wednesday, February 12th. HC Wainwright reiterated a “neutral” rating and issued a $19.00 target price on shares of AnaptysBio in a research report on Tuesday, February 4th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Wolfe Research initiated coverage on AnaptysBio in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 target price for the company. Finally, Guggenheim decreased their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus price target of $37.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.